The Qvar Redihaler by Norton Waterford is different from the majority of inhalers in the market because it is a breath-activating device. The breath-activating technology allows for no-hand breath coordination, and leads to an easier and more accurate inhalation of the medicine. The Qvar Redihaler has three existing patents and a NDA that exist until 2020, so extensive data regarding the mechanics and technology of the Qvar Redihaler is unfortunately unavailable in the public domain. However, we have created a body of research that is helpful for understanding the interworkings of the device below.
There are three existing US patents for the Qvar Redihaler that were recently approved in August 2017. Prior to this, there were two existing US patents for the Qvar Redihaler that have since expired. This patent has been to twenty-six international countries, where Norton Waterford has solidified sixty-six patent family members. The Qvar Redihaler is also protected by a NDA with the patents. With the NDA in place, there are no details available on the exact mechanics of the patents or device. There are five suppliers listed for the generic ingredient in the product, beclomethasone dipropionate. The patent number for the Qval Redihaler is CASRN: 50-02-2UNII: 7S5.
Breath Actuated Devices
Breath-actuated devices contain a "pressurized canister and have a flow-triggered system driven by a spring." This releases the dose during inhalation, and creates a coordinated disbursement of the medicine with the inhalation. Usage errors are shown to be less common with these devices and have the capability to reduce the overall cost of long-term asthma therapy. There are multiple devices that use a breath-actuated system which will be explained below.
Autohaler: This device primes itself when the mouthpiece is opened. "Inhalation triggers a vane mechanism" within the device when a lever on the top has been raised. This results in the device being actuated automatically through a spring and was effective for patients even if they exhaled the medicine immediately.
Eassibreathe: This device has been even easier to use for patients than the Autohaler, due to the device being prepared by inhalation automatically when the mouthpiece is opened. "The Easibreathe contains a pneumatic system, which restrains the operating spring."
K-Hauler: When this device is used, the medicine is actuated into a kinked tube. The kinked tube is then straightened out by a breath operated lever that simultaneously releases the dose. The dust cap is then opened to re-kink the tube and depress the stem of the valve.
The Qval Redihaler is made as a preventative solution to common asthma, asthma attacks and breathing issues. It is not meant to help in the event of an asthma attack, for the drug is released slowly throughout the body. Other than the first usage of the device and if it hasn't been used for ten days, patients are not required to prime or shake the Qval Redihaler. It is also unnecessary to use a spacer or any type of volume holding product when using the product.
It is important to not wash the device or get it wet, and only necessary to clean the mouthpiece off with a cloth every week. Most devices have a dosage counter which counts down the amount of sprays are left in the container. When using the product, the patient only needs to put their mouth on the inhaler and breath in without having to push any part of the inhaler to activate. Many doctors state that inhalers are not being used correctly because patients struggle with hand-breath coordination, therefore are not properly receiving the medicine they have been prescribed. The Qvar Redihaler reduces these inaccuracies and create an easier and more accurate way to receive breathing medication.
DOSAGE AND SIDE EFFECTS
The recommended dosages by the FDA for the Qvar Redihaler are 40 to 80 mcgs for people twelve years or older. The medicine is usually distributed twice a day with twelve hours in between. It is not recommended taking the Qvar Redihaler while on an inhaled corticosteroid.
There has not been substantial research for children under 11 as well as geriatric populations using the medicine, therefore it is not recommended for either of these groups to be using the Qval Redihaler. Pregnant and women who are breast feeding should not be using the product, for there has been minimal research on the effects of the fetus and if the medicine passes through the breast milk. Beclomethasone has been shown to affect children growth rates and can also cause yeast infections in the mouth, sinus pain, headaches and sore throats.
We have researched three common pharmacies and the pricing of the Qval Redihaler at each of them. The product usually comes in 8.7 gs and our research was based off an 80 mcg dosage. At Costco the price of the product is $233.62; at Walmart, the product is $239.99 and at Kroger the price is $240.22.
Overall, the Qval Redihaler distributes the same medicine as other Qval products, but is unique based on the distribution technology. This inhaler is important in helping alleviate the issues many have with hand-breath coordination. The product creates a more accurate distribution of the medicine to those using it, therefore allowing for more effective alleviation. The Qval Redihaler has three US patents expiring in 2020, as well as a NDA that protect the products' technology for Norton Waterford. However, there have been many breath-actuated devices, such as the Qval Redihaler, that have been utilized in the past. These devices have been included for a deeper understanding of the technology that is behind the uniqueness of the Qval Redihaler.